Wassil Jim 4

What Happened

• Wassil Jim, Chief Operating Officer of Vaxcyte (PCVX), reported multiple transactions on July 1, 2026. He sold a total of 2,250 common shares in open-market transactions (1,788 + 456 + 6 shares) for aggregate proceeds of roughly $126,737. On the same day he exercised 516 stock options by paying $5.35 per share ($2,761 total).
• The Form 4 also shows a derivative-related disposal of 516 shares at $0.00, which in filings typically reflects shares surrendered (for example to cover exercise cost or tax withholding) rather than a cash sale. The option exercised is noted as fully vested.

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 6, 2026.
• Open-market sales:
  • 1,788 shares at a weighted-average $56.03 (range $55.60–$56.595) — proceeds $100,182 (F2).
  • 456 shares at a weighted-average $57.47 (range $56.695–$57.59) — proceeds $26,208 (F3).
  • 6 shares at $57.82 — proceeds $347.
  • Total proceeds from sales ≈ $126,737.
• Option exercise:
  • 516 shares acquired via exercise at $5.35/share — cost $2,761. Option fully vested (F4).
  • 516 shares listed as disposed at $0.00 (derivative disposition), suggesting surrender/withholding (see note above).
• Plan/notes: Sales were made under a Rule 10b5‑1 trading plan adopted December 9, 2025 (F1). Weighted-average prices and price ranges are provided in footnotes (F2, F3).
• Shares owned after the transactions: not specified in the supplied summary of this filing.

Context

• This filing shows mostly sales (routine monetization) plus an option exercise. The sales were carried out under a pre-established 10b5‑1 plan, which is commonly used to schedule sales in advance and does not by itself indicate a change in insider sentiment.
• The paired exercise and zero-dollar derivative disposition often reflects a net or cashless-style settlement (shares surrendered for payment or tax withholding). The filing does not state the insider’s motive.